FDA approves generic version of Jazz Pharma's sleep disorder drug

Features Reuters

(Copyright Reuters 2017)

The U.S. Food and Drug Administration said on Tuesday it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with a medical condition that causes excessive daytime sleepiness. (http://bit.ly/2jHzIS9)

Continue Reading Below

Jazz Pharma's shares were down 4.8 percent at $110 in extended trading.

(Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)